key: cord-0805802-2j0wq179
authors: Swol, Justyna; Lorusso, Roberto
title: Additive treatment considerations in COVID‐19 – the clinician´s perspective on extracorporeal adjunctive purification techniques
date: 2020-06-09
journal: Artif Organs
DOI: 10.1111/aor.13748
sha: 6f429767eb20e8e2f11a6b5081a29ebff812f26c
doc_id: 805802
cord_uid: 2j0wq179

The aim of this document is to inform the scientific community of sparse preliminary results regarding advanced supportive therapies and technology‐driven systems in addition to highlighting the benefits and possibilities of performing concise research during challenging times. Advanced organ support for lung and heart offers the possibility to buy the time needed for recovery. However, remaining a bridging strategy, extracorporeal life support cannot act as the ultimate treatment of the underlying COVID‐19 disease. Appropriate patient selection criteria addressed by experts and scientific organizations, such Extracorporeal Life Support Organization and World Health Organization may provide significant help in the difficult decision‐making and to reduce mortality in patients with profound respiratory and/or cardiac failure due to COVID‐19. Severe, systemic cytokine‐mediated inflammation associated with the SARS‐CoV‐2 has also been described. Effects of crosstalk between coagulation and inflammatory pathways appear to significantly affect disease progression and lead to poor outcomes. Multiple therapeutic strategies, including antibody therapies (such as Tocilizumab, Sarilumab, Siltuximab), therapeutic plasma exchange (TPE), and blood purification techniques for direct removal of cytokines, including filtration, dialysis (diffusion), and adsorption are available. Further, we believe, that research should be facilitated and promoted, particularly under the guidance of recognized scientific societies or expert‐based multicenter investigation, with rapid communication of critical and relevant information to enhance better appraisal of patient profiles, complications, and treatment modalities.

Within the past twenty years, diverse viruses, including corona and influenza, have spread worldwide and cause significant mortality and global economic catastrophe. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is very contagious, and infection with this virus has resulted in a significant number of deaths (1) . The number of patients suffering from SARS-CoV-2-related infectious diseases has now passed six million cases with more than 370,000 deaths globally, according to available data (1) . Coronavirus disease 2019 (COVID-19) presents unique clinical and logistical challenges to governments, health-care-practitioners, and healthcare systems. Because of the spread of COVID 19, hospital administrators and policy makers had to face a substantial increase in critical care bed capacity with a focus not just on infrastructure and supplies but also on staff management, including personal protection equipment (2) . Isolation, quarantine, social distancing, and community containment play a pivotal role in public health measures aimed at slowing the spread of this virus (3) . Testing methods for detecting the presence of virus itself (reverse-transcriptase polymerase chain reaction and isothermal nucleic acid amplification), followed by quarantine of those who tested positive and tracing of those with whom the SARS-CoV-2 positive people had contact can result in provable reduction of the spread of the virus in the population (4) (5) (6) . The impact of viral load and exposure time on symptom severity, which might explain the mortality rate of young healthy individuals, still remains uncertain. Due to the novelty of the virus to date, no clinical data for a specific antiviral therapy or a workable vaccination against the virus are available. At present, therapy focuses on supportive treatment, especially in intensive care for very severe cases (2, (7) (8) (9) (10) (11) (12) (13) . Advanced organ support for lung and heart offers the possibility to buy the time needed for recovery (14) (15) (16) . Although the amount of newly published information is enormous, much of this information contains uncertain or dangerous misinterpretations of the virus and treatments (17, 18) . Prospective randomized controlled trials and observational studies based on large cohorts are lacking due to the limitations caused by the global pandemic. The aim of this document is to inform the scientific community of sparse preliminary results regarding advanced supportive therapies and technology-driven systems in addition to highlighting the benefits and possibilities of performing concise research during challenging times.

This article is protected by copyright. All rights reserved Overall, the final denominator for calculating the COVID-19 mortality rate may not be available or may be unknown for now (19) . Public health measures, clinical management, and care of COVID-19 patients and the guideline of admission to hospital for patients with confirmed COVID-19 varied across countries (8, 10, 11, 13, (20) (21) (22) (23) (24) (25) . Healthcare systems in any country also had to face an overwhelming demand for hospital and intensive care unit (ICU) beds (8, 9, 23, 26) .

In case of resource overload, inadequate care of patients with mild symptoms resulted in the development of more severe illness or even death. However, the performance of the healthcare system in each country depended on the strategy that the governments chose to address the outbreak and when the lockdown aimed at flattening the curve was enforced. Also, coordination of capacities and resource availability (hospital and ICU beds, ventilators, extracorporeal life support devices) in national or even international interactive platforms enabled, in some circumstances, adequate help to be provided in addition to the best chance of survival for severely ill patients with good prognosis (27, 28) .

So far, no proven therapy and no vaccination for COVID-19 exist. Unproven therapies have been or are being administered off-label or on a compassionate use basis. Widespread and desperate adoption of mostly different types of pharmacological interventions with little or no supportive evidence based on case series, non-randomized, retrospective cohorts without reasonable benefits was released quite early. However, several agents, such as remdesivir, lopinavir, ritonavir, hydroxychloroquine, tocilizumab, and favipiravir, that were previously used against SARS-and MERS-CoV have been used empirically without definitive recommendation for use (29) (30) (31) (32) . The first and the only placebo-controlled, double-blinded, multi-center RCT of remdesivir was stopped early due to poor recruitment after including 237 patients (33) . Wang et al. observed no effect of remdesivir on any endpoint, including viral load and a very small reduction in the time to clinical improvement (21 vs. 23 days) (33) .

Non-invasive ventilation, high-flow nasal cannula, and corticosteroids serve as the primary supportive approaches before invasive mechanical ventilation (IMV) and prone positioning are considered in more severe cases (2, 7, 10, 12) . First, observations showed that patients intubated on mechanical ventilation had long ICU courses and ventilator-induced lung injury may have occurred during this period (7, 12) . A lower threshold than normal to initiate IMV created two conflicting issues: iatrogenic harm and depletion of finite resources, ICU beds, and ventilators.

The early clinical experience with this emerging pathogen has indicated that approximately 15%-

This article is protected by copyright. All rights reserved 30% of hospitalized patients develop respiratory failure, and 12% require mechanical ventilation with 3% needing extracorporeal life support (ECLS) (13) .

Advanced organ support, such as ECLS, presents complex patient-device interactions in circumstances of already profound inflammatory, cardio-circulatory, and coagulative abnormalities. Remaining a bridging strategy to buy the time to recovery, ECLS cannot act as the ultimate treatment of the underlying COVID-19 disease (14) (15) (16) . The use of ECLS has been described with controversial mortality rate of up to 100% (34) (35) (36) . However, appropriate patient selection criteria addressed by experts and scientific organizations, such as the Extracorporeal Life Support Organization (ELSO, Ann Arbor, MI, USA) may provide significant help in the difficult decision-making (15) . Also, the World Health Organization (WHO, Geneva, Switzerland) guidance document includes a statement to consider referring patients with refractory hypoxemia despite lung-protective ventilation in settings with access to experts in ECLS support (1).

Geographical differences in ECLS case counts are evident, and are likely due to the regional extent and impact of the outbreak and the previously established capacity for ECLS (26, 28, 37-39). The vast majority of ECLS are veno-venous, but the severe cardio-circulatory effects of COVID-19 have given rise to a relative increase in the use of veno-arterial ECLS in almost 5% of the cases (37-39). The goal of ECLS use during a pandemic is to reduce mortality in patients with profound respiratory and/or cardiac failure. Weekly reports of an Euro-ELSO survey on ECLS provision in adult COVID-19 patients in Europe have been released online since March 21, 2020 on the Euro-ELSO website (39). Total counts of COVID-19 confirmed patients and counts of COVID-19 suspected but not confirmed by testing cases on ECLS in the ELSO Registry are displayed is a real-time data stream on the ELSO website (37, 38) .

This article is protected by copyright. All rights reserved

The first reports from China described mainly respiratory and inflammatory symptoms of COVID-19 (21) (22) (23) (40) (41) (42) (43) . The type of respiratory involvement also showed almost normal lung compliance and considerable disease heterogeneity and severity among affected patients, leading some to hypothesize different disease phenotypes (7) . A common observation was the "silent hypoxemia" phenotype of COVID-19, an individual who does not otherwise show signs of respiratory failure (7) . Also, more and more evidences have appeared indicating that patients have a newly kind of hypercoagulability (44) . Early histopathological data showed that pulmonary microvascular thrombosis may play a role in progressive respiratory failure (45, 46) . Furthermore, involvement of the cardiovascular system (41, 47, 48) ranges from myocarditis, cardiac tamponade, and acute pulmonary embolism to cardio-circulatory collapse, often representing the ultimate cause of death. Beyond cardiopulmonary involvement, other organ systems have been severely affected and have shown severe dysfunctions. These dysfunctions included profound immunological impairment, sometimes leading to secondary immunosuppression as demonstrated by lymphocytopenia in more than 80% of the patients (22, 41, 49) . Furthermore, coagulopathy, ranging from a pro-thrombotic to anticoagulated state due to antiphospholipid antibodies with thrombocytopenia. Severe, systemic cytokine-mediated inflammation associated with this virus has been described (42, 43, 45, 46, 49) . Effects of crosstalk between coagulation and inflammatory pathways appear to significantly affect disease progression and lead to poor outcomes (45, 46) . Due to these presentations, COVID-19 should be defined and understood as a systemic disease.

In severe cases, the pronounced release of vasoactive mediators (cytokine storm) was repeatedly observed (42, 43) . Ruan et al. and Zhou et al. have identified a high interleukin 6 (IL-6) level as a potential predictor of a fatal outcome COVID-19 disease as an crease in IL-6 levels result in pronounced vasodilatation and membrane leakage, which ultimately lead to refractory vasoplegia and multiple organ failure (21, 23, 45) . Finally, a sepsis-like syndrome occurred frequently that could have resulted from the virus itself or to a superimposed bacterial infection. Multiple therapeutic strategies, including antibody therapies (such as Tocilizumab, Sarilumab, Siltuximab), therapeutic plasma exchange (TPE), and even direct removal of cytokines, might also mitigate the "cytokine storm" (50) (51) (52) (53) . In general, three main blood purification techniques, including filtration, dialysis (diffusion), and adsorption are available.

This article is protected by copyright. All rights reserved The use of blood purification to improve clinical outcomes is not a novel concept (50, (52) (53) (54) 60) .

In fact, extracorporeal filtration techniques, such as coupled plasma filtration adsorption, have shown promise as a potential adjuvant therapy in sepsis and septic shock (54, 58) . The rationale for the use of hemo-adsorption, double filtration plasmapheresis (DFPP) and plasma exchange (TPE) is the reduction in circulating pro-and anti-inflammatory cytokines (IL-8, -1ra, -1α, -10, and -6) and other circulating mediators, thus avoiding severe complications and facilitating an improvement of patient outcomes (52, 53). The potential effects of blood purification therapy in reducing cytokine storm as a late complication of two critically ill COVID-19 patients were reported by the group from Beijing, China (57) . Furthermore, as the corona viruses are larger than 100 nm, all secondary filtration membranes may work toward the reduction of virus load.

However, targeting the overactive cytokine response with anti-cytokine therapies or immunomodulators should be balanced with maintaining an adequate inflammatory response for pathogen clearance (45, 49) .

This article is protected by copyright. All rights reserved The United States Food and Drug Administration (US FDA, Silver Spring, MD, USA) approved an Investigational Device Exemption (IDE) for a therapeutic hemoperfusion device that removes circulating endotoxin from the bloodstream (PMX, Spectral Medical, Toronto, Canada). The IDE approval has provided the opportunity for the use of PMX in COVID-19 patients suffering from septic shock and is a supplement to the company's current Tigris trial, which is an FDA-approved clinical trial in the US for studying the use of PMX for septic shock. Direct hemoperfusion using a polymyxin B endotoxin-adsorbing column (PMX-DHP) is a modality developed in Japan and marketed as Toraymyxin® (Toray Industries, Tokyo, Japan). PMX-DHP is a polycationic antibiotic column containing multiple polymyxin B-immobilized fibers, which have been shown to neutralize bacterial endotoxins. A major concern related to polymyxin B hemoperfusion, however, is the risk of cartridge clotting, which can cause premature interruption of the treatment and acute blood loss in patients who are already critically ill. As opposed to Emergency Use Authorization (EUA), Spectral's IDE supplement approved by the FDA recognizes that there is sufficient safety and effectiveness data to allow clinicians to use PMX to treat patients who are similar to patients in the Tigris trial and are also COVID-19 positive. Spectral will provide these therapeutic cartridges free of charge.

There are a multitude of adsorption hemofilters currently being investigated, including, but not 

This article is protected by copyright. All rights reserved every 24 hours. Specifically, CytoSorb has been reported to work most effectively when treatment is initiated within 24 h of a sepsis diagnosis. The CytoSorb hemo-adsorption technique is unique in that its efficacy is concentration-dependent. High concentrations of cytokines in the blood will be removed more quickly in comparison to blood with lower cytokine levels. These results indicate that CytoSorb in combination with ECLS is apparently an effective therapy to prevent escalation of sepsis with rapid weaning off high-dose catecholamine infusions and quick reduction in procalcitonin (PCT) and C-reactive protein (CRP) levels. The use of CytoSorb with ECLS was associated with a shorter mean duration on ECMO of 8.2 days (range: 2-23 days) versus 26.5 days (range: 13-30 days) in the control, a rapid reversal of septic shock within 48 hours, and a marked decrease in lactate dehydrogenase and inflammatory markers. The optimal timing for immunomodulatory therapy and impact on ECLS-related inflammation still needs to be furtherly investigated.

To validate the safety and efficacy of this emerging technology, diverse registries have been created.

The International CytoSorb Registry has been established to collect and analyze treatment data from all over the world and is being independently managed by the Center of Clinical Studies at the University of Jena, Germany. Its goal is to track patient mortality (primary endpoint) and secondary outcomes such as hospital-and intensive care unit-length of stay, vasopressor use, renal replacement therapy, and end-organ function. Weekly statistics from the registry data will provide data according to the disease stage in which the treatment was started, the treated plasma volumes for TPE, the number of treatments per number of days, and the physician's judgment of TPE effectiveness.

This article is protected by copyright. All rights reserved 

In the scenario of a severe pandemic, in which resources that are limited for advanced organ support, such as ECLS or blood purification techniques, may be de-prioritized to redirect care towards numerous patients with a higher likelihood of survival (61) . Due to the intensive hospital resource utilization, substantial staff training, and multidisciplinary needs associated with starting an ECLS program, ELSO recommends against starting new ECLS centers for the sole purpose of treating patients with COVID-19 (15) . A list of experienced ECLS centers is provided on the ELSO website (37, 38) .

Treatment under uncertainty and surge conditions, the understandable urge to use untested interventions, staffing and equipment shortages, risk of health care worker infection, and research staff deployment to provide clinical care are also significant barriers against research implementation during a pandemic. Under such conditions, no one really has much time to wait for evidence. Clinical trials have been initiated but the awaited outcome results will not help current patients (62) . Registries may at least provide a rapid response as to why the clinical course is so heterogenous but the critical point remains as to which procedures in COVID-19 illness patients should be initiated (37, 39) . The Thoracic Society led International Task Force recommends that data be collected from COVID-19 patients who have received or are receiving one or more of the interventions suggested in Interim Guidance on Management Pending

Empirical Evidence. The data should be assessed periodically so that patients who received the intervention can be compared to those who did not. Such data will provide interim guidance until superseded by randomized trial results when they become available.

This article is protected by copyright. All rights reserved Epidemiological management, including tests detecting antibodies produced in response to infection in individuals exposed to the virus, clinical interventions, and scientific research needs to be a coordinated. Further research should be facilitated and promoted, particularly under the guidance of recognized scientific societies or expert-based multicenter investigation, with rapid communication of critical and relevant information to enhance better appraisal of patient profiles, complications, and treatment modalities (16, 62) .

With any antiviral treatments, timely administration before complications develop will be crucial.

Randomized controlled trials of the most promising treatments are a leading priority, and, hopefully, the road to an effective treatment and vaccine will not be too long. Interestingly, the development of a successful vaccine at the end of the movie Contagion (2011), one of the infectious disease outbreak and pandemic films, also provides a bit of hope (63) .

This article is protected by copyright. All rights reserved 

COVID-19) 2020

Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak

Public Health Measures and the Reproduction Number of SARS-CoV-2

Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts

Disease Control, Civil Liberties, and Mass Testing -Calibrating Restrictions during the Covid-19 Pandemic

COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Medicine

Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Critically ill patients with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study

Surge capacity of intensive care units in case of acute increase in demand caused by COVID-19 in Australia

Management of COVID-19 Respiratory Distress. JAMA. 2020. Accepted Article This article is protected by copyright

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Extracorporeal Membrane Oxygenation – Crucial Considerations during the Coronavirus Crisis

Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure

Towards precision delivery of ECMO in COVID-19 cardiorespiratory failure

Misinformation During the Coronavirus Disease 2019 Outbreak: How Knowledge Emerges From Noise

Internet Searches for Unproven COVID-19 Therapies in the United States

Denominator matters in estimating COVID-19 mortality rates

Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

Regional Planning for Extracorporeal Membrane Oxygenation Allocation During COVID-19

Managing COVID-19 in Low-and Middle-Income Countries

ECMO Resource Planning in the Setting of Pandemic Respiratory Illness. Annals of the

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Covid-19: a puzzle with many missing pieces

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?

Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients

Extracorporeal Membrane Oxygenation for Coronavirus Disease

Full COVID-19 Registry Dashboard -COVID-19 Cases on ECMO in the ELSO Registry

All rights reserved 39. EuroELSO Survey on ECMO Use in Adult COVID-19 patients in Europe

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet

Cytokine release syndrome in severe COVID-19

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine

Acute Pulmonary Embolism in SARS-CoV-2 Infection Treated with Surgical Embolectomy. The Annals of Thoracic Surgery

COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Cardiovascular Consequences and Considerations of Coronavirus Infection – perspectives for the cardiothoracic anesthesiologist and intensivist during the coronavirus crisis

Coronaviruses and the cardiovascular system: acute and long-term implications

COVID-19, ECMO, and lymphopenia: a word of caution

Impact of Therapeutic Plasma Exchange on Hemodynamic Parameters in Medical Intensive Care Unit Patients: An Observational Study

Therapeutic Plasma Exchange-Does Age Matter? A Single-Center Study

Patient safety technology for microadsorbent systems in extracorporeal blood purification

Blood Purification With CytoSorb in Critically Ill Patients: Single-Center Preliminary Experience

Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19

Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19

A New Application for

Albumin Dialysis in Extracorporeal Organ Support: Characterization of a Putative Interaction Between Human Albumin and Proinflammatory Cytokines IL-6 and TNFα

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Why do we need extracorporeal blood purification for sepsis and septic shock? Artif Organs

A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19

Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances

Assessing the Collateral Damage of the Novel Coronavirus: A Call to Action for the Post-COVID-19 Era. The Annals of Thoracic Surgery

collaboration with ELSO, ISARIC, SPRINT-SARI ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (ECMOCARD)

Infectious Disease Outbreaks, Pandemics, and Hollywood-Hope and Fear